AU2707797A - Methods and means for inhibition of cdk4 activity - Google Patents

Methods and means for inhibition of cdk4 activity

Info

Publication number
AU2707797A
AU2707797A AU27077/97A AU2707797A AU2707797A AU 2707797 A AU2707797 A AU 2707797A AU 27077/97 A AU27077/97 A AU 27077/97A AU 2707797 A AU2707797 A AU 2707797A AU 2707797 A AU2707797 A AU 2707797A
Authority
AU
Australia
Prior art keywords
cdk4
activity
inhibition
methods
sup
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU27077/97A
Other languages
English (en)
Inventor
Kathryn Lindsay Ball
David Philip Lane
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Dundee
Original Assignee
University of Dundee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9609521.1A external-priority patent/GB9609521D0/en
Priority claimed from GBGB9621314.5A external-priority patent/GB9621314D0/en
Application filed by University of Dundee filed Critical University of Dundee
Publication of AU2707797A publication Critical patent/AU2707797A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Plant Substances (AREA)
AU27077/97A 1996-05-08 1997-05-08 Methods and means for inhibition of cdk4 activity Abandoned AU2707797A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9609521.1A GB9609521D0 (en) 1996-05-08 1996-05-08 Substances and their therapeutic use
GB9609521 1996-05-08
GB9621314 1996-10-09
GBGB9621314.5A GB9621314D0 (en) 1996-10-09 1996-10-09 Substances and their therapeutic use
PCT/GB1997/001250 WO1997042222A1 (en) 1996-05-08 1997-05-08 Methods and means for inhibition of cdk4 activity

Publications (1)

Publication Number Publication Date
AU2707797A true AU2707797A (en) 1997-11-26

Family

ID=26309279

Family Applications (1)

Application Number Title Priority Date Filing Date
AU27077/97A Abandoned AU2707797A (en) 1996-05-08 1997-05-08 Methods and means for inhibition of cdk4 activity

Country Status (7)

Country Link
US (3) US6962792B1 (cg-RX-API-DMAC7.html)
EP (1) EP0898580B9 (cg-RX-API-DMAC7.html)
JP (1) JP4205165B2 (cg-RX-API-DMAC7.html)
AT (1) ATE333465T1 (cg-RX-API-DMAC7.html)
AU (1) AU2707797A (cg-RX-API-DMAC7.html)
DE (2) DE69736351T4 (cg-RX-API-DMAC7.html)
WO (1) WO1997042222A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962792B1 (en) 1996-05-08 2005-11-08 Cyclacel Limited Methods and means for inhibition of Cdk4 activity
GB9727277D0 (en) * 1997-12-23 1998-02-25 Medical Res Council Assay
WO1999042834A2 (en) * 1998-02-18 1999-08-26 Theryte Limited Treating cancer
BR9907965A (pt) * 1998-03-23 2000-12-12 Du Pont Fragmento de ácido nucléico isolado, gene quimérico, célula hospedeira transformada, polipetìdios, processo de alteração do nìvel de expressão de uma proteìna ciclina em uma célula hospedeira, método de obtenção de um fragmento de ácido nucleìco, produto e método de avaliação de pelo menos um composto quanto à sua capacidade de inibir a atividade de uma proteìna ciclina
EP1338652A3 (en) * 1998-03-23 2004-05-19 E.I.Du pont de nemours and company Plant cell cyclin genes
EP1140202A1 (en) * 1998-12-24 2001-10-10 Ucb S.A. Peptidic product, process and composition
AU4203300A (en) * 1999-04-07 2000-10-23 E.I. Du Pont De Nemours And Company Cell cycle genes in plants
GB9928323D0 (en) * 1999-11-30 2000-01-26 Cyclacel Ltd Peptides
US20050153894A1 (en) * 1999-11-30 2005-07-14 Cyclacel Limited p21 peptides
GB2369823B (en) * 1999-11-30 2003-06-04 Cyclacel Ltd Assays for cyclin-interacting compounds
US7449544B2 (en) 1999-11-30 2008-11-11 Cyclacel Limited p21 peptides
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
GB0030378D0 (en) 2000-12-13 2001-01-24 Cyclacel Ltd Compound
CA2494236A1 (en) * 2002-08-07 2004-02-19 Exelixis, Inc. Csnk1gs as modifiers of the p21 pathway and methods of use
GB0229151D0 (en) 2002-12-13 2003-01-15 St Georges Entpr Ltd Product and method
US20080026992A1 (en) * 2003-10-20 2008-01-31 Ludger Hengst Tyrosine Phosphorylation of Cdk Inhibitor Proteins of the Cip/Kip Family
AU2004285745A1 (en) * 2003-10-21 2005-05-12 Cyclacel Limited Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy
GB0402653D0 (en) * 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
GB0411791D0 (en) * 2004-05-26 2004-06-30 Cyclacel Ltd Compounds
ES2403558T3 (es) 2004-08-27 2013-05-20 Cyclacel Limited Inhibidores purínicos y pirimidínicos de CDK y su uso para el tratamiento de enfermedades autoinmunitarias
EP1909811B1 (en) * 2005-06-29 2012-02-01 St. George's Enterprises Limited Hox peptides as pbx modulators for the treatment of cancer
EP2224961A1 (en) * 2007-11-26 2010-09-08 The Research Foundation of the State University of New York Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells
US9040046B2 (en) 2011-01-31 2015-05-26 Kai Xu Sodium pump antibody agonists and methods of treating heart disease using the same
CA3096978A1 (en) 2018-04-06 2019-10-10 Oncolyze, Inc. Compositions for use in lysis of selective cancer cells
WO2020055758A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
CN118324906A (zh) * 2024-06-14 2024-07-12 上海交通大学医学院附属上海儿童医学中心 p21特异性修饰的抗体及制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2759164A1 (de) 1977-12-31 1979-07-12 Basf Ag Photopolymerisierbare ueberzugs- und aufzeichnungsmaterialien, enthaltend einen photoinitiator und eine organische halogenverbindung
US5229018A (en) 1986-02-24 1993-07-20 Forrest Gabriel T Completion and workover fluid for oil and gas wells comprising ground peanut hulls
FR2662698A1 (fr) 1990-06-05 1991-12-06 Centre Nat Rech Scient Nouveaux facteurs de croissance neurotropes comprenant un peptide homeoboite.
US5302706A (en) 1991-12-16 1994-04-12 Baylor College Of Medicine Senescent cell derived inhibitors of DNA synthesis
US5596079A (en) 1991-12-16 1997-01-21 Smith; James R. Mimetics of senescent cell derived inhibitors of DNA synthesis
PT665886E (pt) 1992-10-16 2003-10-31 Cold Spring Harbor Lab Rearranjo de complexos de ciclina e suas utilizacoes
GB9305448D0 (en) 1993-03-17 1993-05-05 British Tech Group Semiconductor structure and method of manufacturing same
JP3822232B2 (ja) 1993-08-30 2006-09-13 ベイラー・カレッジ・オブ・メディシン 老化細胞由来ｄｎａ合成阻害因子
WO1995013375A1 (en) 1993-11-10 1995-05-18 The Johns Hopkins University Tumor suppressor waf1
AU2644495A (en) 1994-05-24 1995-12-18 Baylor College Of Medicine Mimetics of senescent cell derived inhibitors of dna synthesis
GB9422175D0 (en) 1994-11-03 1994-12-21 Univ Dundee Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof
GB9509557D0 (en) 1995-05-11 1995-07-05 Univ Dundee PCNA binding substance
WO1997003681A1 (en) 1995-07-20 1997-02-06 Worcester Foundation For Biomedical Research, Inc. Methods for selectively killing or inhibiting the growth of cells expressing the waf1 gene
US5672508A (en) 1996-01-23 1997-09-30 Mitotix, Inc. Inhibitors of cell-cycle progression, and uses related thereto
US6962792B1 (en) 1996-05-08 2005-11-08 Cyclacel Limited Methods and means for inhibition of Cdk4 activity

Also Published As

Publication number Publication date
EP0898580A1 (en) 1999-03-03
JP2000513805A (ja) 2000-10-17
EP0898580B1 (en) 2006-07-19
WO1997042222A1 (en) 1997-11-13
US6962792B1 (en) 2005-11-08
US20080249025A1 (en) 2008-10-09
DE69736351T2 (de) 2007-07-12
DE69736351D1 (de) 2006-08-31
EP0898580B3 (en) 2008-10-29
JP4205165B2 (ja) 2009-01-07
EP0898580B9 (en) 2009-08-12
US20040214765A1 (en) 2004-10-28
DE69736351T4 (de) 2009-07-23
ATE333465T1 (de) 2006-08-15

Similar Documents

Publication Publication Date Title
AU2707797A (en) Methods and means for inhibition of cdk4 activity
Kulikov et al. Mdm2 facilitates the association of p53 with the proteasome
Mei et al. The USP19 deubiquitinase regulates the stability of c-IAP1 and c-IAP2
AU3738397A (en) 2-methoxyestradiol-induced apoptosis in cancer cells
AU4073297A (en) Methods and compositions for the detection of cervical cancer
IL117425A0 (en) Receptor activation by gas6
AU1367095A (en) Effector proteins of rapamycin
WO2001031335A3 (en) Cell proliferation diagnosis and screening for modulators
WO1999006540A3 (en) Inhibitors of cell-cycle progression and uses related thereto
WO1998025598A3 (en) Methods and pharmaceutical compositions for inhibiting tumour cell growth
WO1996034113A3 (en) Methods for the identification of farnesyltransferase inhibitors
AU3801997A (en) Assays for protein kinases using fluorescent protein substrates
WO2001023412A3 (en) Methods of screening for agents which inhibit aggregation of polypeptides
AU5229498A (en) Mutants of the lag-3 proteins, products for the expression of these mutants and use
CA2265444A1 (en) Tnf-beta-like protein for treating prostate cancer, and related nucleic acid molecules, pharmaceutical compositions and methods
AU6865600A (en) Cell proliferation inhibitory protein, polynucleotide, antisense polynucleotide to the polynucleotide, and cell proliferation inhibitors, cancer diagnostics, cancer remedies and compositions for gene therapy by using the same
AU749763C (en) Modification of cereal grain hardness via expression of puroindoline proteins
WO2000078795A3 (en) Rufomycins and derivatives thereof useful as inhibitors of multi-drug resistance associated protein-1 (mrp-1)
AU7216498A (en) Inhibitors of the urokinase receptor
WO2004075839A3 (en) Methods and compositions for modulating apoptosis
Nikolaev et al. PARC: a potential target for cancer therapy
ATE362768T1 (de) Prb2/p130 peptidinhibitoren der cdk2 kinaseaktivität
AU6193699A (en) Antisense-sequences for inhibiting the expression of the adhesion molecule icam-1
WO2004043371A3 (en) Methods and compositions for modulating p53 transcription factor
AU3880900A (en) Surface localized colligin/hsp47 in carcinoma cells